|Cell Therapeutics, Inc.|
3101 Western Avenue
United States - Map
Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat; and a strategic collaboration with Baxter International Inc. to develop and commercialize Pacritinib. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
|Dr. James A. Bianco M.D.,
Principal Founder, Chief Exec. Officer, Pres and Exec. Director
|Dr. Jack W. Singer M.D.,
Co-Founder, Exec. VP of Global Medical Affairs & Translational Medicine and Exec. Director
|Mr. Louis A. Bianco CPA,
Co-Founder, Principal Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin. and Sec.
|Dr. Matthew J. Plunkett Ph.D.,
Exec. VP of Corp. Devel.
|Ms. Monique M. Greer Sr.,
Sr. VP of Corp. Communications and Investor Relations
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|